{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:29:51Z","timestamp":1783452591368,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","award":["NCT02244502"],"award-info":[{"award-number":["NCT02244502"]}],"id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ygyno.2018.07.018","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T11:24:23Z","timestamp":1532690663000},"page":"471-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study"],"prefix":"10.1016","volume":"150","author":[{"given":"Ignace","family":"Vergote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Van Nieuwenhuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2018.07.018_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0015","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","article-title":"Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study","volume":"35","author":"Pignata","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0020","doi-asserted-by":"crossref","first-page":"viii61","DOI":"10.1093\/annonc\/mdr518","article-title":"Update of randomized trials in recurrent disease","volume":"22","author":"Pujade-Lauraine","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9378(12)91832-3","article-title":"Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial","volume":"170","author":"Seewaldt","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0030","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/bjc.1995.453","article-title":"Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience","volume":"72","author":"Gore","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0040","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0050","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous Cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0055","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian Cancer: a randomized multicenter phase II trial of the north-eastern German society of gynecological oncology ovarian cancer study group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0065","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0070","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian Cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0075","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0080","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in Cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0085","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.ygyno.2018.07.018_bb0090","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.lungcan.2013.06.025","article-title":"A phase I\/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer","volume":"81","author":"Pless","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0100","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0105","article-title":"A pilot study of TTFields concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma. | 2016 Gastrointestinal Cancers Symposium | Abstracts | Meeting Library","volume":"34","author":"Rivera","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"S329","key":"10.1016\/j.ygyno.2018.07.018_bb0110","article-title":"OA22.01 STELLAR - interim results of a phase 2 trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma","volume":"12","author":"Grosso","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0115","first-page":"5","article-title":"Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo","volume":"0","author":"Voloshin","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0120","series-title":"Clinical Trials in Recurrent Ovarian Cancer","first-page":"771","volume":"21","author":"Friedlander","year":"2011"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0125","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80\u202fmg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a gynecologic oncology group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","article-title":"Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer","volume":"30","author":"Karlan","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0145","first-page":"383","article-title":"A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients","volume":"23","author":"Kaern","year":"2002","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0150","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdu363","article-title":"A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer","volume":"25","author":"McNeish","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0155","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American joint committee on cancer: the 7th edition of the AJCC Cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0160","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","volume":"90","author":"Buda","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0165","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the north-eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0170","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1073\/pnas.90.20.9552","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations","volume":"90","author":"Jordan","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0175","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.018_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6649-9-1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)","volume":"9","author":"Kirson","year":"2009","journal-title":"BMC Med. Phys."},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2018.07.018_bb0185","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","article-title":"Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo","volume":"41","author":"Giladi","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0190","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jso.21288","article-title":"Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer","volume":"99","author":"Sehouli","year":"2009","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.07.018_bb0195","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.03.011","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0200","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.07.018_bb0205","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:38:39Z","timestamp":1758771519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818310825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0090825818310825"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}